Luxoft (NYSE:LXFT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Luxoft is a global IT service provider of innovative technology solutions that delivers measurable business outcomes to multinational companies. Its offerings encompass strategic consulting, custom software development services, and digital solution engineering. Luxoft enables companies to compete by leveraging its multi-industry expertise in the financial services, automotive, communications, and healthcare & life sciences sectors. Its managed delivery model is underpinned by a highly-educated workforce, allowing the Company to continuously innovate upwards on the technology stack to meet evolving digital challenges. Luxoft has more than 12,900 employees across 42 offices in 21 countries within five continents, with its operating headquarters office in Zug, Switzerland. “
Best Performing Stocks To Watch For 2021: Interpublic Group of Companies, Inc. (IPG)
The Interpublic Group of Companies, Inc. provides advertising and marketing services worldwide. It operates through two segments, Integrated Agency Networks and Constituency Management Group. The company offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines. It also provides various diversified services, including public relations, meeting and event production, sports and entertainment marketing, corporate and brand identity, and strategic marketing consulting. The company's brands comprise McCann, MullenLowe, IPG Mediabrands, Carmichael Lynch, Deutsch, Hill Holliday, and The Martin Agency, as well as Foote, Cone & Belding. The company was formerly known as McCann-Erickson Incorporated and changed its name to The Interpublic Group of Companies, Inc. in January 1961. The Interpublic Group of Companies, Inc. was founded in 1902 and is headquartered in New York, New York.
At the time of publication, FNF stock earned an A rating in Dividend Grader.
TRADEMARK VIOLATION WARNING: “Northern Trust Corp Boosts Stake in Interpublic Group of Companies Inc (IPG)” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4213616/northern-trust-corp-boosts-stake-in-interpublic-group-of-companies-inc-ipg.html.
Interpublic Group of Companies Inc (NYSE:IPG)Q4 2018 Earnings Conference CallFeb. 13, 2019, 8:30 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Interpublic Group of Companies (NYSE:IPG) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Interpublic is benefitting from higher organic revenue growth. The company's digital capabilities, diversified business model and geographic reach offer a distinctive competitive advantage. It continues to look for strategic investments and buyouts to expand in high-growth regions and key world markets. Interpublic’s consistent efforts to reward its shareholders with dividend and share repurchases are appreciable. Shares of the company have outperformed its industry in the past year. However, the company’s global presence makes it vulnerable to foreign currency fluctuations. Its cash position is affected by seasonality in business. Client concentration can be a major hindrance to Interpublic’s business. A debt-laden balance sheet is another concern.”
Best Performing Stocks To Watch For 2021: Progenics Pharmaceuticals Inc.(PGNX)
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.
Azedra
Azedra is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands. The Company has completed enrollment in pivotal Phase IIb clinical trial under Special Protocol Assessment (SPA).
1404 (trofolastat)
The Company's 1404 (trofolastat) is a technetium-99m labeled small molecule, which binds prostate specific membrane antigen (PSMA) and is used as an imaging agent to diagnose and detect localized prostate cancer, as well as soft tissue and bone metastases. The Company has completed a global multi-centered Phase II study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer and initiated a multi-center, open-label Phase III trial to determine the sensitivity and specificity of 1404 to correctly identify whether or not patients have clinically prostate cancer
PyL ((18F) DCFPyL)!
The Company's PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine. The Company's studies show the uptake of PyL is high in sites of putative metastatic lesions and primary tumors, suggesting the potential for high sensitivity in detecting prostate cancer.
1095
The Company's 1095 is a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule, which is designed to deliver a dose of radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The Company focuses on initiating a Phase I clinical study.
PSMA ADC
PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer. The Company's Phase II, multicenter clinical trial to assess the safety, tolerability and anti-tumor activity of PSMA ADC, has been completed in both the chemotherapy refractory and chemotherapy naive patients with metastatic castration-resistant prostate cancer (mCRPC).
Relistor
The Company's Relistor is used as a treatment for Opioid-Induced Constipation (OIC), which decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. Relistor-Subcutaneous injection is engaged in the treatment of OIC in patients with non-cancer pain, and is marketed in the United States. Relistor-Oral has completed Phase III clinical trials.
PRO 140
The Company's PRO 140 is a humanized IgG4 monoclonal antibody directed against C-C chemokine receptor type 5 (CCR5), a molecular portal that human immunodeficiency virus (HIV) uses to enter T-cells. PRO 140 blocks the predominant HIV subtype (R5) entry into T-cells by masking this required co-receptor, CCR5. PRO ! 140 has b! een the subject of over seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects.
The Company competes with Merck & Co., Inc., Sucampo Pharmaceuticals, Inc., Shionogi & Co., Theravance, Inc., Johnson & Johnson, Medivation, Inc., Bayer HealthCare Pharmaceuticals Inc. and Aytu Bioscience Inc.
Advisors' Opinion:- [By Logan Wallace]
Get a free copy of the Zacks research report on Progenics Pharmaceuticals (PGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have received an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $13.33.
Best Performing Stocks To Watch For 2021: PNC Financial Services Group, Inc. (PNC)
Headquartered in Pittsburgh, Pennsylvania, we are one of the largest diversified financial services companies in the United States. We have businesses engaged in retail banking, corporate and institutional banking, asset management, and residential mortgage banking, providing many of our products and services nationally, as well as other products and services in our primary geographic markets located in Pennsylvania, Ohio, New Jersey, Michigan, Illinois, Maryland, Indiana, Florida, North Carolina, Kentucky, Washington, D.C., Delaware, Virginia, Alabama, Georgia, Missouri, Wisconsin and South Carolina. We also provide certain products and services internationally. At December 31, 2015, our consolidated total assets, total deposits and total shareholders' equity were $358.5 billion, $249.0 billion and $44.7 billion, respectively. Advisors' Opinion:
- [By Garrett Baldwin]
See Now: Our founder just released his No. 1 pick for 2019. Don't miss this. See the urgent briefing here…
Walt Disney Co. (NYSE: DIS) unveiled its highly anticipated streaming service on Thursday. The service, Disney+, will launch Nov. 12 and cost $6.99 per month or $69 per year. The service will include television shows and films from its extended universe of programming – including the Star Wars and Marvel series. Disney said that all of its new films will be available on the service as soon as their theatrical windows have ended. In merger news, Chevron Corp. (NYSE: CVX) announced plans to purchase Anadarko Petroleum Corp. (NYSE: APC) as the oil major continues to push into the U.S. shale business. Shares of APC popped 32% in pre-market hours after Chevron announced the $33 billion bid. This is the largest energy merger since 2016 after Royal Dutch Shell Plc. (NYSE: RDS.A) purchased BG Group. The news sent shares of companies that operate in the Permian basin in West Texas even higher this morning. Look for other earnings reports from PNC Financial Services Group Inc. (NYSE: PNC) and Infosys Ltd. (NASDAQ: INFY). This Is How You Can Grow Incredibly Rich Buying Straight-Up StocksRight now, even with all the market uncertainty, there's truly a ridiculous amount of money to be made from stocks if you follow this secret.
- [By Money Morning Staff Reports]
Buffett is no stranger to banks. He's owned a piece of Wells Fargo & Co. (NYSE: WFC) for 19 years. And recently, he took some big chunks of some of the other big and well-known banks, including Bank of America Corp. (NYSE: BAC), Goldman Sachs Group Inc. (NYSE: GS), Bank of New York Mellon Corp. (NYSE: BK), and PNC Financial Services Group Inc. (NYSE: PNC).
Best Performing Stocks To Watch For 2021: Enpro Industries(NPO)
EnPro Industries, Inc. (EnPro), incorporated on January 11, 2002, is engaged in the designing, developing, manufacturing, and marketing engineered industrial products. The Company operates through three segments: Sealing Products, Engineered Products and Power Systems. The Company has approximately 60 primary manufacturing facilities located over 10 countries, including the United States.
Sealing Products Segment
The Company's Sealing Products segment designs, manufactures and sells sealing products, including metallic, non-metallic and composite material gaskets; dynamic seals; compression packing; resilient metal seals; elastomeric seals; hydraulic components; expansion joints; pipeline casing spacers/isolators; casing end seals; modular sealing systems for sealing pipeline penetrations; hole forming products; manhole infiltration sealing systems; safety-related signage for pipelines; heavy-duty truck wheel-end component systems, including brake products, brake drums, suspension products and tire pressure management products; bellows and bellows assemblies; pedestals for semiconductor manufacturing, and polytetrafluoroethylene (PTFE) products. These products are used in a range of industries, including chemical and petrochemical processing, petroleum extraction and refining, pulp and paper processing, power generation, food and pharmaceutical processing, primary metal manufacturing, mining, water and waste treatment, heavy-duty trucking, aerospace, medical, filtration and semiconductor fabrication.
The Company's Sealing Products segment includes over three operating divisions, such as Garlock, Technetics and Stemcor that serve a range of industries. The Garlock family of companies' designs, manufactures and sells sealing products. Gasket products are used for sealing flange joints in chemical, petrochemical and pulp and paper processing facilities. Its products are also used in sanitary markets. The Company sells these gasket products under the Garlock, Gylon, ! Blue-Gard, Stress-Saver, Edge, Graphonic, Bio-Pro, and Flexseal brand names. Technetics Group designs, manufactures and sells metal seals. Its brands include Helicoflex, Belfab, Feltmetal, PlastomerTM, BioGuardianTM and Origraf. Stemco designs, manufactures and sells heavy-duty truck wheel-end components and systems. Its product brands include STEMCO, STEMCO Kaiser, STEMCO Duroline, STEMCO Crewson, STEMCO Motor Wheel, Grit Guard, Guardian HP, Voyager, Discover, Endeavor, Pro-Torq, Sentinel, Data Trac, DataTrac, QwikKit, Centrifuse, AerisTM, BAT RF, TrailerTail, Spring Ride and Super Cushion. Sealing Products segment sells products to industrial agents and distributors, original equipment manufacturers (OEMs), engineering and construction firms and end users around the world.
Engineered Products Segment
The Company's Engineered Products segment includes approximately two industrial products businesses, including GGB and Compressor Products International (CPI). The Engineered Products segment sells its products to a diverse customer base using a combination of direct sales and independent distribution networks across the world.
GGB designs, manufactures and sells self-lubricating, non-rolling, metal polymer, solid polymer and filament wound bearing products, as well as aluminum bushing blocks for hydraulic applications. The bearing surfaces are made of PTFE or a mixture that includes PTFE to provide maintenance-free performance and reduced friction. GGB's bearing products perform as sleeve bearings or thrust washers under conditions of no lubrication, minimal lubrication or pre-lubrication. These products are used in a range of markets, such as the automotive, pump and compressor, construction, power generation and general industrial markets. GGB has approximately 20,000 bearing part numbers of various designs and physical dimensions. GGB sells products under the DU, DP, DX, DS, HI-EX, EP, SY, HPMB and GAR-MAX brand names.
CPI designs, manufactures, sell! s and ser! vices components for reciprocating compressors and engines. These components, which include packing and wiper rings, piston and rider rings, compressor valve assemblies, divider block valves, compressor monitoring systems, lubrication systems and related components are utilized in the refining, petrochemical, natural gas gathering, storage and transmission, and general industrial markets. Brand names for the Company's products include Hi-Flo, Valvealert, Mentor, Triple Circle, CPI Special Polymer Alloys, Twin Ring, Liard, ProFlo, Neomag, CVP, XDC, POPR and Protecting Compressors World Wide.
Power Systems Segment
The Company's Power Systems segment designs, manufactures, sells and services heavy-duty, medium-speed diesel, natural gas and dual fuel reciprocating engines. The Company sells these products and services under the Fairbanks Morse Engine brand name. Products in this segment include licensed heavy-duty, medium-speed diesel, natural gas and dual fuel reciprocating engines, in addition to its own designs. The reciprocating engines range in size from 700 to 31,970 horsepower and from 5 to 20 cylinders. These products are used in marine, oil and gas, and power generation markets. The United States Government and the general markets for marine propulsion, power generation, and pump and compressor applications use these products and services.
The Company's Power Systems segment sells its products and services to customers across the world, including shipyards, municipal utilities, institutional and industrial organizations, sewage treatment plants, nuclear power plants, and offshore oil and gas platforms.
The Company competes with A.W. Chesterton Company, Klinger Group, Teadit, Lamons, SIEM/Flexitallic, SKF USA Inc., Federal-Mogul Corporation, Meritor, Firestone, Saint-Gobain, Eaton Corporation, Parker Hannifin Corporation, Miropro Co. Ltd., Kolbenschmidt Pierburg AG, Saint-Gobain's Norglide division, Federal-Mogul Corporation, Cook Compression, Hoer! biger Cor! poration, Graco, MTU, Caterpillar Inc., and Wartsila Corporation.
Advisors' Opinion:- [By Max Byerly]
EnPro Industries, Inc. (NYSE:NPO) has been assigned an average rating of “Hold” from the eight research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $91.60.
- [By Max Byerly]
Get a free copy of the Zacks research report on EnPro Industries (NPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
EnPro Industries, Inc. (NYSE:NPO) SVP Jon D. Rickers sold 500 shares of the firm’s stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $75.63, for a total value of $37,815.00. Following the completion of the transaction, the senior vice president now owns 6,215 shares of the company’s stock, valued at approximately $470,040.45. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Best Performing Stocks To Watch For 2021: ICON plc(ICLR)
ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It develops, manages, and analyzes programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical development services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, risk-based monitoring, clinical data management, interactive response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, market access and commercialization services, strategic analysis and data operations, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, and study protocol preparation. The company's clinical development services also comprise regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, strategic resourcing, electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, biomarker development, adaptive trial design and execution, medical device trials, and healthcare communication services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.
COPYRIGHT VIOLATION NOTICE: “Castleark Management LLC Sells 18,945 Shares of Icon Plc (ICLR)” was published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/4205668/castleark-management-llc-sells-18945-shares-of-icon-plc-iclr.html. Icon PLC (NASDAQ:ICLR)Q4 2018 Earnings Conference CallFeb. 21, 2019, 7:30 p.m. ET Operator Anavex Life Sciences (NASDAQ:AVXL) and Icon (NASDAQ:ICLR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings. Get a free copy of the Zacks research report on Icon (ICLR) For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment